Diagnostic Value of Glypican3, Heat Shock Protein 70 and Glutamine Synthetase in Hepatocellular Carcinoma Arising in Cirrhotic and Non-Cirrhotic Livers
- PMID: 29892181
- PMCID: PMC5992316
- DOI: 10.1016/j.jceh.2017.09.005
Diagnostic Value of Glypican3, Heat Shock Protein 70 and Glutamine Synthetase in Hepatocellular Carcinoma Arising in Cirrhotic and Non-Cirrhotic Livers
Abstract
Background and objectives: Histopathological distinction of various nodular lesions in liver with sufficient sensitivity and specificity is a challenge even in an expert set up. The panel of immunohistochemical markers composed of glutamine synthetase (GS), Glypican3 (GPC3) and heat shock protein 70 (HSP70) was recommended by the International Consensus Group for Hepatocellular Neoplasia group for the differentiation of high grade dysplastic nodule and early hepatocellular carcinoma (HCC). The panel has been extensively validated in the western population. This study aims to test this panel on Indian population on resected, explanted and autopsy cirrhotic and non-cirrhotic liver specimens of HCC.
Methodology: This study was conducted on 39 such liver specimens (12 cirrhotic, 12 pre-cirrhotic and 11 non-cirrhotic, non-fibrotic livers), including 35 cases of HCC over a period of 12 years. Immunohistochemistry was performed with antibodies against GS, GPC3 and HSP70 on the sections containing both malignant and dysplastic nodules.
Results: The diagnostic yield depended upon the nature of background liver pathology and was found to be high for only those HCCs arising in cirrhotic background, when positivity of any two markers was taken to be in favor of HCC (sensitivity-58.33%; specificity-100%). GS had a sensitivity and Negative predictive value of 100% for HCCs arising in cirrhotic livers.
Conclusions: Strong positivity for GS is a highly sensitive marker for HCC in a cirrhotic background regardless of the differentiation of the tumor in Indian population. This may be due to preferential activation of Wnt pathway in Indian patients with cirrhosis. The sensitivity of the panel was too low for detecting HCCs arising in non-cirrhotic livers, even in the pre-cirrhotic chronically inflamed livers, even though the specificity was high. GPC3 and HSP70 appear to be useful as individual markers for HCCs arising in non-cirrhotic livers.
Keywords: C, cirrhotic; GPC3, Glypican3; GS, glutamine synthetase; Glypican3; HCC, hepatocellular carcinoma; HGDN, high grade dysplastic nodule; HSP70, heat shock protein 70; ICGHN, International Consensus Group for Hepatocellular Neoplasia; LGDN, low grade dysplastic nodules; NCNF, non-cirrhotic, non-fibrotic livers; PC, pre-cirrhotic; dysplastic nodules; glutamine synthetase; heat shock protein 70; hepatocellular carcinoma.
Figures


Similar articles
-
Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis.Hepatology. 2007 Mar;45(3):725-34. doi: 10.1002/hep.21531. Hepatology. 2007. PMID: 17326147
-
Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma.Gut. 2012 Oct;61(10):1481-7. doi: 10.1136/gutjnl-2011-301862. Epub 2012 Jan 27. Gut. 2012. PMID: 22287594
-
Improving pathological early diagnosis and differential biomarker value for hepatocellular carcinoma via RNAscope technology.Hepatol Int. 2020 Jan;14(1):96-104. doi: 10.1007/s12072-019-10006-z. Epub 2019 Dec 12. Hepatol Int. 2020. PMID: 31832976
-
Diagnosis of well-differentiated hepatocellular lesions: role of immunohistochemistry and other ancillary techniques.Adv Anat Pathol. 2011 Nov;18(6):438-45. doi: 10.1097/PAP.0b013e318234abb4. Adv Anat Pathol. 2011. PMID: 21993269 Review.
-
Early hepatocellular carcinoma and dysplastic nodules.Semin Liver Dis. 2005;25(2):133-42. doi: 10.1055/s-2005-871193. Semin Liver Dis. 2005. PMID: 15918142 Review.
Cited by
-
Diagnostic accuracy and prognostic significance of Glypican-3 in hepatocellular carcinoma: A systematic review and meta-analysis.Front Oncol. 2022 Sep 23;12:1012418. doi: 10.3389/fonc.2022.1012418. eCollection 2022. Front Oncol. 2022. PMID: 36212469 Free PMC article.
-
Glutamine metabolic reprogramming in hepatocellular carcinoma.Front Mol Biosci. 2023 Aug 11;10:1242059. doi: 10.3389/fmolb.2023.1242059. eCollection 2023. Front Mol Biosci. 2023. PMID: 37635935 Free PMC article. Review.
-
Non-Cirrhotic Liver is Associated with Poor Prognosis of Hepatocellular Carcinoma: A Literature Review.Med Sci Monit. 2019 Sep 3;25:6615-6623. doi: 10.12659/MSM.915722. Med Sci Monit. 2019. PMID: 31479436 Free PMC article. Review.
-
Update on hepatocellular carcinoma: Pathologists' review.World J Gastroenterol. 2019 Apr 14;25(14):1653-1665. doi: 10.3748/wjg.v25.i14.1653. World J Gastroenterol. 2019. PMID: 31011252 Free PMC article. Review.
-
Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma.Saudi J Gastroenterol. 2020 Oct;26(Suppl 1):S1-S40. doi: 10.4103/sjg.SJG_477_20. Saudi J Gastroenterol. 2020. PMID: 33078723 Free PMC article. No abstract available.
References
-
- Pathologic diagnosis of early hepatocellular carcinoma: a report of the International Consensus Group for Hepatocellular Neoplasia. Hepatology. 2009;49:658–664. - PubMed
-
- Capurro M., Wanless I.R., Sherman M. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125:89–97. - PubMed
-
- Midorikawa Y., Ishikawa S., Iwanari H. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer. 2003;103:455–465. - PubMed
-
- Nakatsura T., Yoshitake Y., Senju S. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun. 2003;306:16–25. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources